Form 4: Maze Therapeutics Director Gifts Common Stock

Maze Therapeutics Director Charles J. Homcy reported gifting 28,423 shares of common stock, reducing his direct beneficial ownership.

Summary

• Charles J. Homcy, a Director of Maze Therapeutics, Inc. (MAZE), reported a disposition of common stock.
• On October 23, 2025, Mr. Homcy gifted 28,423 shares of Maze Therapeutics common stock.
• The transaction was a gift, meaning no consideration was received, and is exempt under Rule 16b-5.
• Following this transaction, Mr. Homcy directly beneficially owns 29,624 shares of common stock.
• Additionally, 7,422 shares are indirectly beneficially owned through the Charles J. Homcy Revocable Trust.

Sentiment

Score: 5

Explanation: The filing reports a gift of shares by a director, which is a personal transaction and does not directly reflect on the company's operational or financial performance. It results in a reduction of direct insider ownership, which is generally considered neutral from a company performance perspective.

Future Outlook

NA

Industry Context

This filing reports a specific insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Gift of 28,423 shares of common stock by Director Charles J. Homcy to an undisclosed recipient, for no consideration.

Stakeholder Impact

• Shareholders: The transaction represents a reduction in direct insider ownership, which is a factual change in holdings but does not directly impact the company's operational or financial performance for other shareholders.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, insider transaction, stock gift, Charles J. Homcy, director